Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-11-28Clinical Trial Update: EEG@HOME (Phase 3b of the Project, Interviews) [NA]
The EEG@HOME Phase 3b epilepsy trial sponsored by University Hospital Ghent has been terminated.
-
CLINICAL_TRIALS withdrawal · 2017-11-28Clinical Trial Update: EEG@HOME (Phase 4 of the Project) [NA]
The EEG@HOME trial in epilepsy has been withdrawn; no further activity is planned.
-
CLINICAL_TRIALS research · 2017-11-28Clinical Trial Update: Use of Sodium Bicarbonate in Patients Treated With Topiramate [NA]
Clinical trial update examining the use of sodium bicarbonate in patients treated with topiramate, in the context of epilepsy and metabolic …
-
CLINICAL_TRIALS trial_result · 2017-11-28Clinical Trial Update: EEG@HOME (Phase 3a of the Project, Comparison of EEG-recordings) [NA]
The EEG@HOME Phase 3a trial investigating EEG-recording comparisons for epilepsy has completed, providing an update on the study status.
-
FDA approval · 2017-11-24FDA Approved: TOPIRAMATE — Original Application (Zydus Lifesciences Limited)
FDA approves the original generic application for Topiramate from Zydus Lifesciences Limited, enabling a generic version to reach the market…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-11-20FDA Approved: ACETAZOLAMIDE — Original Application (Strides Pharma Science Limited)
FDA approved an original application for acetazolamide from Strides Pharma Science Limited, establishing a generic version of the drug. The …
-
FDA approval · 2017-11-17FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Emergency Medical Services and Epilepsy in Switzerland
A Swiss clinical trial investigating emergency medical services and epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures [Phase 3]
Phase 3 trial update evaluating phenobarbital as adjunctive therapy in partial onset seizures; the study has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-07Clinical Trial Update: Functional Link Between Hippocampal and Vestibular Systems: a Pilot Study in Epilepsy Surgery [NA]
A completed pilot clinical trial investigating the functional link between hippocampal and vestibular systems in epilepsy surgery, sponsored…
-
CLINICAL_TRIALS research · 2017-11-06Clinical Trial Update: Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors
A completed epidemiologic follow-up study of seniors newly diagnosed with epilepsy to track long-term outcomes.
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Depression and Health Outcomes in Refractory Epilepsy [Phase 3]
A Phase 3 trial assessing depression and health outcomes in patients with refractory epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Effect of Short-term Theta Frequency Stimulation of the Vagus Nerve on Cognition in Patients With Refractory Epilepsy [NA]
The Clinical Trial Update reports that the study evaluating short-term theta-frequency stimulation of the vagus nerve to assess cognition in…
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Brain Dynamics in Different Stages of Arousal and Anesthesia
This clinical trial update reports that the study on brain dynamics across arousal and anesthesia stages in epilepsy has been terminated.
-
FDA approval · 2017-11-03FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., authorizing changes included in the supplemental sub…
-
FDA approval · 2017-11-03FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2017-10-31FDA Approved: CEREBYX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Cerebyx (fosphenytoin sodium) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA label_change · 2017-10-31FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
Supplemental NDA application for DILANTIN-125 (phenytoin) by Viatris Specialty LLC, likely involving labeling changes or addition of a dosag…
-
CLINICAL_TRIALS research · 2017-10-30Clinical Trial Update: Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy
A completed study validating the Spanish version of the Quality of Life in Epilepsy questionnaire (QOLIE-10) for epilepsy patients; the focu…
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: Spectral Dynamic Imaging of Cognitive Functions in Epileptic Patients Explored Stereoelectroencephalography [NA]
A study explored spectral dynamic imaging of cognitive functions in epilepsy patients using stereoelectroencephalography. The trial status i…
-
FDA approval · 2017-10-25FDA Approved: LEVETIRACETAM — Original Application (Dr.Reddy's Laboratories Inc)
FDA approved Dr. Reddy's Laboratories Inc. levetiracetam injection under an Original Application (ANDA 206880). This marks market approval o…
-
FDA approval · 2017-10-24FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA XR (levetiracetam) from UCB, expanding the product to an extended-release formulation…
-
FDA approval · 2017-10-24FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) filed by UCB, Inc.
-
FDA approval · 2017-10-24FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA page indicating a supplemental application for KEPPRA (levetiracetam) by UCB, Inc. under NDA 021035.
-
FDA approval · 2017-10-18FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Neurontin (gabapentin) filed by Parke-Davis Div of Pfizer Inc. The approval concerns a modif…